

India reports 1,60,695 cases and 864 deaths

Maharashtra reports 51,751 infections, 258 casualties

SPECIAL CORRESPONDENT
CHENNAI

As of 11.55 p.m. on Monday, India reported 1,60,695 COVID-19 cases and 864 deaths.

The figures do not include cases and deaths from Ladakh and Manipur. The data is sourced from covid19india.org, an independent aggregator of daily COVID-19 figures.

Only 11.8 lakh tests were conducted on Sunday (for which results were made available on Monday), about 2.3 lakh fewer than Saturday's but 2.8 lakh more than the previous Sunday. A total of 25,78,06,986 samples have been tested in the country as of April 11 since the beginning of the pandemic, says the ICMR.

The country has so far reported a total of 1,36,86,074 cases and 1,71,073 deaths.

Maharashtra reported 51,751 infections (accounting for nearly 33% of the new cases) on Monday, followed by Uttar Pradesh with 13,604

Changing hotspots

From 63% of India's cases between March 15 and 21 (Week 5), Maharashtra's share reduced to just 42% between April 5 and 11 (W8). The share of Chhattisgarh and U.P. has surged

State	Weeks							
	W1	W2	W3	W4	W5	W6	W7	W8
MH*			55%	61%	63%	60%	54%	
CG**				2%	3%	4%	5%	8%
U.P.							3%	7%
KA***	3%	3%	3%	3%	4%	4%	5%	5%
Delhi						2%	3%	5%
T.N.	4%	3%	3%	3%	3%	3%	4%	4%
Kerala		23%	15%	9%	5%	3%	3%	3%

MH*: MAHARASHTRA | CG**: CHHATTISGARH | KA***: KARNATAKA

and Chhattisgarh with 13,576. Maharashtra also recorded the most casualties (258) on Monday. Chhattisgarh followed with 107 deaths, while Uttar Pradesh and Delhi had 72 each.

Over 10.45 crore vaccine doses were administered in India as of 7 a.m. on Monday.

From 63% of India's cases between March 15 and 21, Maharashtra's share re-

duced to 42% between April 5 and 11. In the same period, Chhattisgarh's share increased from 3% to 8%, and that of Uttar Pradesh increased from 1% to 7%. The share of Tamil Nadu and Karnataka remained stable in the range of 3% to 5%.

Kerala's share has been decreasing. Between February 15 and 21, its share was 34%. Between April 5 and 11, it reduced to 3%.

FROM PAGE ONE

SEC approves Russia's Sputnik V vaccine

Sputnik V, developed by Russia's Gamaleya Research Institute of Epidemiology and Microbiology, claims to be one of the three vaccines in the world with efficacy of over 90%.

"The vaccine's efficacy is confirmed at 91.6% based on the analysis of data on 19,866 volunteers, who received both the first and second doses of the Sputnik V vaccine or placebo at the final control point of 78 confirmed COVID-19 cases," noted the information released on the vaccine's official website.

RDIF to produce shots

It adds that the vaccine supplies for the global market will be produced by the Russian Direct Investment Fund (RDIF) international part-

ner market the vaccine in India, RDIF has tied up with other Indian companies - Hetero Biopharma, Gland Pharma, Stelis Biopharma and Virchow Biotech - to produce 850 million doses of Sputnik V in the country every year.

"RDIF jointly with partners and manufacturers is ramping up the production of Sputnik V. The cost of one dose of the vaccine for international markets is less than \$10 (Sputnik V is a two dose vaccine). The (freeze-dried form) of the vaccine can be stored at a temperature of +2 to +8 degrees Celsius, which allows for easy distribution worldwide, including hard-to-reach regions," noted the website.

Dr. Reddy's Labs, which is conducting a trial on the Sputnik V's suitability on In-